For the mathematically challenged, the real value breaks down like this:
$3B/year in earnings - $68M in costs = $2.932B/EARNINGS.
Divide that by the 28M shares outstanding (not just 25M float) yields $105/share ($104.714M to be exact).
So the earnings based valuation is:
$1,050/share at a PE of 10
$2,100/share at a PE of 20
$4,200/share at a PE of 40
It is MATH, no wonder the shorts don't understand it.
So with this stock heading to more than $1,000/share, even if someone lost a significant amount shorting, they could make it all back and then some as this stock continues higher. Make sure the patient count keeps bumping up. Or invest in SRPT like you mentioned, or maybe REGN. Always a way to make it back.
They can't debate the numbers or the valuation, so they make up lies as they lose their butts in that bad short position. Sadly, most shorts still haven't covered yet with more than 3M shorted shares still out there. That means it is going to get WORSE for them as the stock goes higher.